Take­da to pull key hy­poparathy­roidism drug from the mar­ket af­ter years of man­u­fac­tur­ing woes

Take­da on Tues­day morn­ing made an an­nounce­ment that al­most 3,000 peo­ple with the rare dis­ease known as hy­poparathy­roidism were fear­ing.

Due to un­re­solved sup­ply is­sues and man­u­fac­tur­ing woes, Take­da said it will cut its loss­es and dis­con­tin­ue its hy­poparathy­roidism drug, known as Nat­para (parathy­roid hor­mone), halt­ing all man­u­fac­tur­ing of the drug by the end of 2024, but the en­tire in­ven­to­ry will be avail­able un­til de­plet­ed or ex­pired, a com­pa­ny spokesper­son said via email.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.